Pre-made Abrilumab benchmark antibody ( Whole mAb, anti-α4β7/Integrin alpha 4 beta 7 therapeutic antibody, Anti-LPAM‑1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Abrilumab biosimilar, Whole mAb, Anti-α4β7/Integrin alpha 4 beta 7 Antibody: Anti-LPAM‑1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Abrilumab (INN; development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.This drug was developed by MedImmune.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-005-1mg	1mg	3090
GMP-Bios-ab-005-10mg	10mg	Inquiry
GMP-Bios-ab-005-100mg	100mg	Inquiry
GMP-Bios-ab-005-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Abrilumab biosimilar, Whole mAb, Anti-α4β7/Integrin alpha 4 beta 7 Antibody: Anti-LPAM‑1 therapeutic antibody
INN Name	Abrilumab
Target	α4β7
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	Amgen;AstraZeneca
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Crohn's disease;Ulcerative colitis
Development Tech	na